Nasal high flow (NHF) during exercise has failed to boost endurance time in patients with chronic obstructive pulmonary disease (COPD) who are recovering from acute exacerbation, as shown in a recent study.
As-needed budesonide–formoterol (ICS* + LABA**) reliever therapy was more effective than maintenance low-dose budesonide plus as-needed terbutaline (maintenance ICS + as-needed SABA***) for preventing severe exacerbations in patients with mild asthma, according to the PRACTICAL study presented at ERS 2019.
Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.
Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.
About one-third of patients with severe asthma who are on high-dose inhaled corticosteroids (ICS) are also receiving excessive doses of oral corticosteroids (OCS), reveals a study presented at the ERS 2019 Meeting.
Use of the Zephyr endobronchial valve (EBV) led to significant improvements in a range of patient-reported outcomes (PROs) including multiple domains of respiratory symptoms and quality of life (QoL) in patients with severe emphysema, according to the post hoc results of the LIBERATE* trial presented at ERS 2019.
Preliminary real-world findings of the REALITI-A* study, presented at ERS 2019, have demonstrated a significant reduction in asthma exacerbations with mepolizumab, a result comparable to that of regulatory clinical trials with this drug.
Having elevated blood eosinophil counts (BEC) along with three other clinical characteristics help identify a subgroup of patients with COPD* who are most likely to benefit from benralizumab in terms of exacerbation reduction, according to a prespecified pooled analysis of the phase III GALATHEA and TERRANOVA** trials.
Exposure to air pollution increases the risk of death in infants and impairs lung function in young children, according to two studies presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).
The use of low-dose indacaterol acetate/mometasone furoate (IND/MF), a long-acting β2-agonist/inhaled corticosteroid (LABA/ICS) combination, significantly improves trough FEV1* in symptomatic patients with poorly controlled asthma, according to the QUARTZ** study presented at ERS 2019.
The use of e-cigarettes changes the innate defence protein profiles in airway secretions, a new study has shown. These changes may lead to questions about e-cigarettes as the supposed healthier alternative to smoking.
Investigators from The University of Hong Kong (HKU) recently identified a mutation in H7N9 virus which causes the virus to possess a higher ability to infect humans while maintaining its ability to circulate effectively in poultry.